top of page

TrippBio, Inc.

TrippBio, Inc. Stock 1
TrippBio is developing a new, therapeutic application of an FDA-approved drug with a high probability to be proven safe and efficacious in the treatment and prevention of the SARS-CoV-2 virus that causes COVID-19.


Crowd Score
There is a newer open investment round for this company - click here to view
Our take:

Thanks, catch you soon!

Sign up to receive weekly deal alerts and top news

Round Performance

Amount Raised


Average Investment


Average Per Day


# of Investors


Investors vs. Capital Raised

Investment Type

Common Stock

Round Valuation


Minimum Investment


Price Per Share


Investment Details

Early Bird Perks

Perk description
Perk level (dollars)
Perk level (days)

No early bird perks for this round!

Screen Shot 2020-07-15 at 12.01.28

View early bird perks, company financials, valuation methods, and more

Similar Investments

Phoenix PharmaLabs Inc
Common Stock
bottom of page